Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFD | P00746 | 2/20 | 0.54 |
| ▸ | PTGDR2 | Q9Y5Y4 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.44 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.44 |
| ▸ | TSHR | P16473 | 3/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 2/20 | 0.44 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.44 |
| ▸ | HPGD | P15428 | 2/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.44 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.44 |
| ▸ | HMGB1 | P09429 | 1/20 | 0.44 |
| ▸ | GGT1 | P19440 | 1/20 | 0.44 |
| ▸ | BLM | P54132 | 1/20 | 0.44 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.44 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | MAOA | P21397 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25027 | 0.85 | CFD (0.73) | CFDPTGDR2ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL789388 | 0.85 | PTGDR2 (0.63) | CFDPTGDR2ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL477809 | 0.84 | MAPT (0.55) | PTGDR2ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL30362156 | 0.84 | MAPT (0.55) | PTGDR2ALDH1A1KDM4EHSD17B10HPGD | |
| SCHEMBL11330589 | 0.82 | KDM4E (0.57) | CFDALDH1A1KDM4EHSD17B10TSHR | |
| SCHEMBL239981 | 0.82 | CFD (0.50) | CFDALDH1A1KDM4EHSD17B10TSHR | |
| SCHEMBL3453790 | 0.81 | TSHR (0.58) | CFDPTGDR2ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL1603859 | 0.81 | HSD17B10 (0.58) | CFDPTGDR2ALDH1A1KDM4EHSD17B10 | |
| SCHEMBL1162227 | 0.81 | CFD (0.49) | CFDALDH1A1KDM4EHSD17B10TSHR | |
| SCHEMBL1021383 | 0.80 | CFD (0.51) | CFDALDH1A1KDM4ETSHRHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11911353-B2 | Fatty acid synthase inhibitor and application thereof | JIANGNAN UNIVERSITY (CN) | 2024-02-27 | — | — | US | disclosed |
| US-11911353-B2 | Fatty acid synthase inhibitor and application thereof | JIANGNAN UNIVERSITY (CN) | 2024-02-27 | — | — | US | disclosed |
| EP-1615897-B1 | PYRIMIDINONE COMPOUNDS AS CALCILYTICS | NPS PHARMA INC (US) | 2010-11-24 | — | — | EP | disclosed |
| US-7491728-B2 | Pyrimidinone compounds as calcilytics | SMITHKLINE BEECHAM CORP. (US) | 2009-02-17 | — | — | US | disclosed |
| EP-1615897-A4 | PYRIMIDINONE COMPOUNDS AS CALCILYTICS | NPS PHARMA INC (US) | 2008-07-23 | — | — | EP | disclosed |
| US-20070197555-A1 | Pyrimidinone Compounds As Calcilytics | GLAXOSMITHKLINE LLC | 2007-08-23 | — | — | US | disclosed |
| CN-1835928-A | Pyrimidone compounds as calcium-sensitive receptor antagonists | NPS PHARMA INC (US) | 2006-09-20 | — | — | CN | disclosed |
| EP-1615897-A2 | PYRIMIDINONE COMPOUNDS AS CALCILYTICS | NPS PHARMACEUTICALS, INC. (US) | 2006-01-18 | — | — | EP | disclosed |
| WO-2004092120-A2 | PYRIMIDINONE COMPOUNDS AS CALCILYTICS | NPS PHARMACEUTICALS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| WO-1998027080-A1 | CHROMONES USEFUL AS FUNGICIDES | AGREVO UK LIMITED (GB) | 1998-06-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11911353-B2 | Fatty acid synthase inhibitor and application thereof | FASN, SCD, FADS2 | CFD 4819/4885PTGDR2 2694/4885ALDH1A1 1287/4885 |
| US-20070197555-A1 | Pyrimidinone Compounds As Calcilytics | TYMP, DPYD, UMPS | CFD 1492/4885PTGDR2 639/4885ALDH1A1 2151/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.